← All trials
NCT07080229
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Jan 31, 2026
- First posted
- Jul 23, 2025
- Last posted
- Aug 21, 2025
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suez Canal UniversityLead sponsor
- Suez Canal UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.